Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Royal Marsden NHS Foundation Trust
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Intensity Therapeutics, Inc.
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
University of Miami
Columbia University
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Eli Lilly and Company
Fred Hutchinson Cancer Center
Sarcoma Alliance for Research through Collaboration